Coegin PharmaNGM:COEGIN +5.22%30 Days Payable is 471.17 as of Mar. 2026, which is 97% below its 10-year median of 15,772.21. GuruFocus rates NGM:COEGIN with a GF Score™ of 30/100. The stock has 2 warning signs investors should review. Among 702 Biotechnology companies, Coegin Pharma ranks better than 64.25% on this metric.
The historical rank and industry rank for Coegin Pharma's Days Payable or its related term are showing as below:
NGM:COEGIN'
s Days Payable Range Over the Past 10 Years
Min: 12.41 Med: 15772.21 Max: 44712.5
Current: 210.18
During the past 9 years, Coegin Pharma's highest Days Payable was 44712.50. The lowest was 12.41. And the median was 15772.21.
NGM:COEGIN's Days Payable is ranked better than 64.25% of 702
companies
in the Biotechnology industry
Industry Median: 113.56
vs NGM:COEGIN: 210.18
Coegin Pharma's Days Payable
declined
from Mar. 2025 (14,018.28) to Mar. 2026 (471.17).
It may suggest that Coegin Pharmaaccelerated paying its suppliers.
Coegin Pharma Days Payable Related Terms
Coegin Pharma Days Payable Historical Data
* Premium members only.
The historical data trend for Coegin Pharma's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NGM:COEGIN vs VRTX, REGN, ALNY: Days Payable Comparison
For the Biotechnology subindustry, Coegin Pharma's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Coegin Pharma Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Coegin Pharma's Days Payable distribution charts can be found below:
* The bar in red indicates where Coegin Pharma's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Coegin Pharma's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Coegin Pharma (NGM:COEGIN) has a Days Payable of 471.17 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Coegin Pharma and its competitors. This is 97% below median its historical median of 15,772.21. Over the past decade, Coegin Pharma's Days Payable has ranged from 12.41 to 44,712.50. According to the industry distribution chart, Coegin Pharma ranks #251 out of 702 companies in the Biotechnology industry, placing it in the top 35.8%.
Is Coegin Pharma's Days Payable too high?
Coegin Pharma's current Days Payable of 471.17 is 97% below median its 10-year median of 15,772.21. Over the past 10 years, this metric has ranged from a low of 12.41 to a high of 44,712.50. The Biotechnology industry median Days Payable is 113.56. Coegin Pharma's value of 471.17 is 314.9% above this industry median. Based on the distribution chart, Coegin Pharma ranks #251 out of 702 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Coegin Pharma has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Coegin Pharma's Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Coegin Pharma ranks #251 out of 702 companies for Days Payable. This puts Coegin Pharma in the upper half of its industry. The industry median Days Payable is 113.56. Coegin Pharma's value of 471.17 is 314.9% above this benchmark. Historically, Coegin Pharma's own Days Payable has ranged from 12.41 to 44,712.50 over the past decade. While the company's 10-year median is 15,772.21 vs. the industry median of 113.56, Coegin Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.56, based on 702 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Coegin Pharma's current Days Payable of 471.17 is 314.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Coegin Pharma and its competitors. For the Biotechnology industry, the median Days Payable is 113.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Coegin Pharma's current Days Payable is 471.17, which is 97% below median its own 10-year median of 15,772.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Coegin Pharma stock overvalued right now?
Coegin Pharma (NGM:COEGIN) has a current Days Payable of 471.17. The current Days Payable is 471.17, which is 97% below median its 10-year median of 15,772.21 and 314.9% above the Biotechnology industry median of 113.56. Coegin Pharma's overall GF Score™ is 30/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Coegin Pharma (NGM:COEGIN), the current Days Payable is 471.17 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Coegin Pharma AB is a Swedish biotechnology company with projects in hair growth, skin pigmentation, heart attacks, and leukemia. Its project portfolio builds on three distinct, patented technology platforms: the FOL peptide technology, the pigmentation peptide technology, and the cPLA2 alpha technology. The company's project portfolio consists of both cosmetic dermatology and drug development projects. Currently, it is focused on the cosmetic dermatology projects, which include the NPP-4 project for skin pigmentation and the Follicopeptide project for hair growth. In addition, the company's project portfolio also includes three drug development projects: FOL026, for the treatment of myocardial infarction (heart attack); AVX420 for the treatment of leukemia; and AVX001.
30GF Score
Get the complete analysis for NGM:COEGIN
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NGM:COEGIN has been successfully added to your 
